{"database": "lobbying", "table": "lobbying_activities", "rows": [[2025497, "f7d6f86b-4e75-489c-93eb-b788ce3dc79e", "Q3", "WINNING STRATEGIES WASHINGTON", 50796, "KALEO", 2017, "third_quarter", "PHA", "Pharmaceutical drug development including epinephrine for anaphylaxis", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE", 30000, null, 0, 0, "2017-10-16T14:57:04.083000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2025497"], "units": {}, "query_ms": 12.661962071433663, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}